The late chromatoid body component TSSK2 is involved in translational regulation in elongating spermatids in mice
: Lehti, Mari S; Ma, Lin; Kärnä, Salli; Laasanen, Samuli; Ahmedani, Ammar; Olotu, Opeyemi; Bourgery, Matthieu; Tran, Panyi; Sironen, Anu; Kotaja, Noora
Publisher: Bioscientifica
: 2025
Reproduction
: e250297
: 170
: 6
: 1470-1626
: 1741-7899
DOI: https://doi.org/10.1530/REP-25-0297
: https://doi.org/10.1530/rep-25-0297
: https://research.utu.fi/converis/portal/detail/Publication/504677496
Spermatogenesis culminates in a dramatic morphological transformation, including a tight compaction of the chromatin and nuclear reshaping that largely silences transcription. Due to transcriptional silencing, the production of sperm-specific proteins needed for the morphological transformation requires active storage and translational regulation of mRNAs transcribed in earlier cell types. The germline-specific ribonucleoprotein (RNP) granule, the chromatoid body (CB), accumulates RNAs and has a role in RNA regulation in early haploid cells (round spermatids). In late haploid cells (elongating spermatids), the CB is transformed into the so-called late-CB, whose function in RNA regulation has remained elusive. Here we characterized the function of the late-CB by identifying proteins and RNAs interacting with the known late-CB marker, testis-specific serine/threonine-protein kinase 2 (TSSK2). We showed that TSSK2 and the late-CB associate with translation initiation factors and ribosomal proteins. Furthermore, we revealed an association of TSSK2 with a specific set of mRNAs that are enriched in polysome fractions in elongating spermatids, supporting the role of the late-CB in temporally regulated translation. These results link the function of the late-CB to RNA regulation during late spermatogenesis for the first time, providing important novel information about the RNA regulatory processes required for spermatogenesis and male fertility.
:
This work was supported by the Jalmari and Rauha Ahokas Foundation (MSL), Research Council of Finland (NK: 315948, 361207; MSL: 321398), Jane and Aatos Erkko Foundation (NK), and Novo Nordisk Foundation (NK). AS was funded by BBSRC grant BB/V011251/1.